Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2003

View Archived Issues

Improved angiographic diagnosis reported with gadofosveset sodium

Evidence of antitumor activity for Xcellerated T-cells and IL-2 in renal cell carcinoma

Drug-induced hypothermia protects against ischemic damage to the brain

Cethromycin has superior efficacy compared to erythromycin against enterococci in vitro and in vivo

Second- and third-generation oral contraceptives used in female hirsutism

Antiinflammatory effects described for thalidomide in sepsis

News-breaking molecule: the first and only reported potent inhibitor of human asparagine synthase

Two novel series of S1P1/edg1 agonists reported by Merck & Co.

Euroceltique claims new modulators of VR1 and/or mGluR receptors

Merck KGaA scientists discover new factor Xa/factor VIIa inhibitors

Novel 5-HT1A agonists with utility as antipsychotics and in Parkinson's disease therapy

4SC presents potassium channel modulators for respiratory disorders and other uses

Novel heparanase inhibitors and their use as antitumor agents described in recent patent

CV Therapeutics patent covers adenosine A1 agonists for arrhythmia, heart failure, etc.

New phase III trial of Humira in psoriatic arthritis

SBIR grant supports development of ALTU-140 for chronic abdominal pain

Improved vision observed in phase I/II trial of squalamine in wet AMD

Orphan drug grant awarded in support of Veronate

Enrollment under way in pivotal trial of iseganan for VAP

MT-100 NDA accepted for filing

Efficacy reported in phase II trial of IL-1 Trap for RA

Development of SCV-07 oral formulation receives funding

Orally active Syk inhibitor exerts antiinflammatory effects in rodent model of asthma

Bactericidal effects described for TD-6424 against Gram-positive strains

Anti-HIV pyridine oxide derivatives may have second target in addition to RT

Highly specific GSK-3beta inhibitor from AstraZeneca with neuroprotective effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...